| Gene Symbol | SCO2 |
|---|---|
| Full Name | Cytochrome c Oxidase Assembly Factor SCO2 |
| Chromosomal Location | 22q13.33 |
| NCBI Gene ID | [6309](https://www.ncbi.nlm.nih.gov/gene/6309) |
| OMIM | [604272](https://www.omim.org/entry/604272) |
| Ensembl ID | [ENSG00000130489](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130489) |
| UniProt ID | [O43819](https://www.uniprot.org/uniprot/O43819) |
| Protein Length | 262 amino acids |
| Molecular Weight | ~29 kDa |
| Associated Diseases | Leigh syndrome, Fatal infantile cardiomyopathy, Myopathy, Encephalopathy |
SCO2 (Synthesis of Cytochrome c Oxidase 2) encodes a mitochondrial protein essential for the assembly of cytochrome c oxidase (COX), also known as Complex IV of the mitochondrial respiratory chain. This protein functions as a copper chaperone, delivering copper to the Cu_A site of COX, a critical step in the formation of this essential enzyme complex[1].
Cytochrome c oxidase is the terminal enzyme of the mitochondrial electron transport chain, responsible for transferring electrons from cytochrome c to molecular oxygen and generating the proton gradient that drives ATP synthesis. Proper COX assembly requires not only the 13 mitochondrial-encoded subunits but also numerous nuclear-encoded assembly factors, including SCO2[2].
Mutations in SCO2 are among the most common causes of severe mitochondrial disorders in infancy, causing fatal cardiomyopathy, Leigh syndrome, and myopathy. These disorders underscore the critical importance of mitochondrial copper homeostasis and COX assembly for cellular energy production, particularly in tissues with high metabolic demands such as the heart and skeletal muscle[3].
SCO2 functions as a specialized copper chaperone within the mitochondrial matrix:
The Cu_A center consists of two copper atoms coordinated by amino acid residues from COX1. Proper assembly requires precise delivery of copper atoms, a function performed by SCO2 in collaboration with its homolog SCO1[1:1].
SCO2 works closely with SCO1 (Synthesis of Cytochrome c Oxidase 1), another mitochondrial copper chaperone:
| Function | SCO1 | SCO2 |
|---|---|---|
| Primary role | Copper delivery to COX | Copper insertion and COX assembly |
| Expression | Ubiquitous | Highest in muscle |
| Phenotype of deficiency | Severe encephalomyopathy | Cardioencephalomyopathy |
The SCO1-SCO2 complex is essential for COX assembly. While SCO1 appears to be the primary copper donor, SCO2 plays a critical role in the subsequent steps of copper insertion and stabilization of the Cu_A site[1:2].
SCO2 is localized to the mitochondrial matrix:
The protein forms part of COX assembly intermediates that include COX1, COX2, and other assembly factors. These intermediates progress through a stepwise assembly process to form the mature enzyme complex[2:1].
The first described SCO2 mutations caused fatal infantile cardiomyopathy with COX deficiency:
The cardiac phenotype reflects the particularly high energy requirements of the myocardium, which is heavily dependent on oxidative phosphorylation[3:1].
SCO2 mutations are a recognized cause of Leigh syndrome (subacute necrotizing encephalomyelopathy):
The encephalopathic presentation reflects the brain's high energy demands and vulnerability to mitochondrial dysfunction[4].
SCO2 mutations can cause isolated or combined encephalomyopathies:
The phenotypic spectrum reflects the tissue distribution of SCO2 expression and the severity of the mutation[5].
SCO2 mutations lead to COX deficiency, which disrupts the electron transport chain:
This energy deficit is particularly damaging to neurons, which have limited capacity for glycolytic energy production and require continuous ATP supply for membrane potentials, neurotransmitter cycling, and axonal transport[6].
Mitochondrial dysfunction leads to increased oxidative stress:
Oxidative stress contributes to neuronal death through multiple pathways, including activation of apoptotic cascades and damage to cellular components[7].
Mitochondrial dysfunction disrupts calcium homeostasis:
Mitochondrial dysfunction triggers neuronal apoptosis:
SCO2 is expressed in tissues with high metabolic activity:
| Tissue | Expression Level |
|---|---|
| Heart | Very high |
| Skeletal muscle | Very high |
| Brain (cerebral cortex) | Moderate to high |
| Cerebellum | Moderate to high |
| Liver | Moderate |
| Kidney | Moderate |
The high expression in heart and skeletal muscle explains the predominant muscle and cardiac involvement in SCO2-related disorders.
Currently available treatments for SCO2-related disorders include:
Several therapeutic approaches are under investigation:
Gene therapy approaches face unique challenges due to mitochondrial genetics:
For severe cases, mitochondrial replacement therapy may offer future options:
Patients with SCO2 mutations require:
SCO2 function intersects with several key neurodegenerative mechanisms:
Leary SC, Kaufman BA, Peccia J, Shoubridge EA. SCO1 and SCO2 function as copper chaperones for cytochrome c oxidase biogenesis. Human Molecular Genetics. 2004. ↩︎ ↩︎ ↩︎
Barrientos A, Gouget K, Picard M, Tzagoloff A. Cytochrome c oxidase assembly: a puzzle of many pieces. Physiological Reviews. 2002. ↩︎ ↩︎
Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, Krishna S, Walker W, Selby J, Glerum DM, Coster RV, Lyon G, Scalisi A, Panetta M, Boggs S, Smith C, Partridge J, Whitham R, Schubert K, Hillman S, Hartsell M, Tono H, Lerner C, DiMauro S, Hirano M. SCO2 mutations cause fatal infantile cardiomyopathy and cytochrome c oxidase deficiency. Nature Genetics. 1999. ↩︎ ↩︎
Parker WD, Parks JK, Sano T, Haas R. Cytochrome c oxidase deficiency and the molecular basis of Leigh syndrome. Journal of Inherited Metabolic Disease. 2003. ↩︎
Jaberi E, Chitsazian F, Tazir M, Alavi S, Rohani M, Shahidi G, Zaman T, Zare M, Bahhi M, Najafi S, Behfar S, Darvish H, Rouleau GA, Al-Din AM, Tadmouri GO, Kahrizi K, Najmabadi H. Clinical spectrum of SCO2 mutations: from infantile cardioencephalomyopathy to isolated cytochrome c oxidase deficiency. Brain Development. 2015. ↩︎
Mattson MP, Gleichmann M, Cheng A. Energy failure and the pathogenesis of neurodegeneration. Progress in Brain Research. 2008. ↩︎
Lin MT, Beal MF. Mitochondrial oxidative stress and neurodegeneration. Nature. 2006. ↩︎